| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 07/11/2006 | CA2207282C Functionalized nanotubes |
| 07/11/2006 | CA2205564C Pharmaceutical compositions comprising nitric oxide-releasing biopolymers |
| 07/11/2006 | CA2185803C Emulsified drug delivery systems |
| 07/11/2006 | CA2157921C Pharmaceutical compositions comprising paracetamol and l-cysteine or a precursor thereof |
| 07/11/2006 | CA2117536C Immunological detection of organophosphates |
| 07/06/2006 | WO2006072084A2 Methods for enhancing the quality of life of a growing animal |
| 07/06/2006 | WO2006071919A2 Methods for inhibiting a decline in learning and/or memory in animals |
| 07/06/2006 | WO2006071860A1 Poly(ester amide) block copolymers |
| 07/06/2006 | WO2006071801A2 Polymer-von willebrand factor-conjugates |
| 07/06/2006 | WO2006071712A1 Oral compositions containing oxidized camellia |
| 07/06/2006 | WO2006071694A1 Visco-supplement composition and methods |
| 07/06/2006 | WO2006071373A1 Stabilization of viral compositions |
| 07/06/2006 | WO2006071110A1 Biodegradable hydrogels |
| 07/06/2006 | WO2006070930A1 Method for stabilizing anti-dementia drug |
| 07/06/2006 | WO2006070856A1 Sesamin/episesamin compositions |
| 07/06/2006 | WO2006070845A1 Quick disintegration tablet and method of producing the same |
| 07/06/2006 | WO2006070781A1 Matrix-type controlled release preparation comprising basic substance or salt thereof, and process for production of the same |
| 07/06/2006 | WO2006070735A1 Stable granular pharmaceutical composition of solifenacin or its salt |
| 07/06/2006 | WO2006070726A1 N-acetylglucosamine tablet disintegrating in oral cavity and process for producing the same |
| 07/06/2006 | WO2006070705A1 Intraoral disintegration type solid preparation containing povidone iodine |
| 07/06/2006 | WO2006070673A1 Indometacin-containing adhesive patch |
| 07/06/2006 | WO2006070672A1 Hydrous adhesive patch |
| 07/06/2006 | WO2006070578A1 Band seal for hard capsule |
| 07/06/2006 | WO2006070129A1 Injectable or orally deliverable formulations of azetidine derivatives |
| 07/06/2006 | WO2006070093A1 Composition comprising solubilized adapalene with cyclodextrins |
| 07/06/2006 | WO2006069782A2 Lipid complexes coated with peg and their use |
| 07/06/2006 | WO2006069742A1 Urethane compound comprising an incorporated polyether group-containing silicone derivative and a nitrogen heterocycle |
| 07/06/2006 | WO2006069578A1 Hyaluronic acid linked with a polymer of an alpha hydroxy acid |
| 07/06/2006 | WO2006069540A1 Burn-treating drug delivery system containing trehalose and hyaluronic acid and its producing method |
| 07/06/2006 | WO2006050165A3 Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis |
| 07/06/2006 | WO2006044856A3 Use of a2a adenosine receptor agonists |
| 07/06/2006 | WO2006044503A3 Compounds for nonsense suppression, use of these compounds for the manufacture of a medicament for treating somatic mutation-related diseases |
| 07/06/2006 | WO2005072776A3 Liposomal formulations of the antineoplastic agents |
| 07/06/2006 | WO2004062603A3 Methods of treating lung diseases |
| 07/06/2006 | US20060149182 Wound dressing materials comprising complexes of anionic polysaccharides with silver |
| 07/06/2006 | US20060149039 Pseudo-native chemical ligation |
| 07/06/2006 | US20060149034 Homing peptides to receptors of heart vasculature |
| 07/06/2006 | US20060148982 Drug delivery |
| 07/06/2006 | US20060148907 Topical antinflammatory preparations of y-terpinene |
| 07/06/2006 | US20060148906 Fluoroether compositions and methods for inhibiting their degradation in the presence of a lewis acid |
| 07/06/2006 | US20060148900 Method for treating a mammal by administration of a compound having the ability to release CO, compounds having the ability to release CO and pharmaceutical compositions thereof |
| 07/06/2006 | US20060148878 Pseudopolymorphic forms of carvedilol |
| 07/06/2006 | US20060148826 Stable aqueous solutions of risperidone and methods for their preparation |
| 07/06/2006 | US20060148761 Lipids |
| 07/06/2006 | US20060148757 Method of inhibiting formation of volatile aldehydes and/or decomposition of fatty acids and use thereof |
| 07/06/2006 | US20060148756 Amphiphilic macrocyclic derivatives and their analogues |
| 07/06/2006 | US20060148728 Novel podophyllotoxin compositions |
| 07/06/2006 | US20060148718 complex of cytotoxic agent to polypeptides; amino acid sequence proteolytic splitting protate specific antigen; therapy for protate cancer and benign prostate hyperplasia |
| 07/06/2006 | US20060148698 Storage-stable fibrinogen solutions |
| 07/06/2006 | US20060148691 Sustained release preparation for therapy of coronary stenosis or obstruction |
| 07/06/2006 | US20060148682 Identifying substrate of an enzyme that is secreted by MCF7/6, HepG2, or HT29 cells; covalently attaching by amidation or esterification the substrate to drug to form a prospective tumor-activated prodrug; drug screening and testing; antitumor, antiinflammatory and anticarcinogenic agents; diagnosis |
| 07/06/2006 | US20060148124 Nanoparticle conjugates and method of production thereof |
| 07/06/2006 | US20060148086 Vault and vault-like carrier molecules |
| 07/06/2006 | US20060147546 Compound consisting of precipitated silica and phosphate and use thereof as nutrient intake liquid support and as anticaking agent with nutrient intake |
| 07/06/2006 | US20060147544 Use of Emu Oil and its various fractions as a carrier for antifungal, antibacterial, and antiviral medications & preparations |
| 07/06/2006 | US20060147525 Lipophilic drug compositions |
| 07/06/2006 | US20060147521 Sustained release ranolazine formulations |
| 07/06/2006 | US20060147514 Method for introducing antisense oligonucleotides into eucaryotic cells |
| 07/06/2006 | US20060147513 Methods of forming targeted liposomes loaded with a therapeutic agent |
| 07/06/2006 | US20060147497 Administration form and kit for the oral administration of active substances, vitamins and/or nutrients and use thereof |
| 07/06/2006 | US20060147496 Diagnosis of irritable bowel disorders; fibromyalgia; chronic fatique syndrome; antidepressants; tinnitus; autism; autoimmune disease; Crohn's disease; quantitative analysis of serotonine, bile acid in sample |
| 07/06/2006 | US20060147495 Amino acid-based nutritional formulation |
| 07/06/2006 | US20060147494 Bioactive compounds protection method and compositions containing the same |
| 07/06/2006 | US20060147493 Packaging and dispensing of rapid dissolve dosage form |
| 07/06/2006 | US20060147480 FDA Orange book listed patent for Follitropin alpha/beta a fertility drug; stable formulation, nonprecipitating, includes Pluronic F68 (aka Poloxamer 188), m-cresol as bacteriostat, diluent |
| 07/06/2006 | US20060147457 Purified composition of bispecific molecules and methods of production |
| 07/06/2006 | US20060147411 Novel compounds for the treatment of sickle cell disease |
| 07/06/2006 | US20060147409 Biodegradable hydrogel having a visualization agent that reflects or emits light at a wavelength detectable to a human eye for minimal invasive surgery; crosslinked synthetic polymer having electrophilic functional groups and dilysine, trilysine or tetralysine; dyes provide green color |
| 07/06/2006 | US20060147392 Agent for dissolving dental calculi and dental caries |
| 07/06/2006 | US20060147388 Pharmaceutical compositions for nasal delivery |
| 07/06/2006 | US20060147386 System and method for intranasal administration of lorazepam |
| 07/06/2006 | US20060147380 Integrin targeted imaging agents |
| 07/06/2006 | US20060147376 Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier |
| 07/06/2006 | US20060147373 Compositions and methods for the diagnosis and treatment of tumor |
| 07/06/2006 | US20060146644 System for producing micro-cluster liquids |
| 07/06/2006 | CA2593064A1 Hyaluronic acid linked with a polymer of an alpha hydroxy acid |
| 07/06/2006 | CA2593032A1 Lipid complexes coated with peg and their use |
| 07/06/2006 | CA2592827A1 Methods for enhancing the quality of life of a growing animal |
| 07/06/2006 | CA2592532A1 Sesamin/episesamin compositions with improved bioavailability |
| 07/06/2006 | CA2592323A1 Stabilization of viral compositions |
| 07/06/2006 | CA2592184A1 Oral compositions containing oxidized camellia |
| 07/06/2006 | CA2591852A1 Polymer-von willebrand factor-conjugates |
| 07/06/2006 | CA2591761A1 Stable particulate pharmaceutical composition of solifenacin or salt thereof |
| 07/06/2006 | CA2591323A1 Urethane compound comprising an incorporated polyether group-containing silicone derivative and a nitrogen heterocycle |
| 07/06/2006 | CA2591294A1 Composition comprising solubilized adapalene with cyclodextrins |
| 07/06/2006 | CA2589632A1 Injectable non-aqueous suspension |
| 07/06/2006 | CA2589374A1 Antibodies directed to gpnmb and uses thereof |
| 07/06/2006 | CA2587388A1 Visco-supplement composition and methods |
| 07/06/2006 | CA2586895A1 Injectable or orally deliverable formulations of azetidine derivatives |
| 07/05/2006 | EP1676832A2 Compounds and compositions for delivering active agents |
| 07/05/2006 | EP1676588A1 Polyarginine-modified liposome capable of transferring into nucleus |
| 07/05/2006 | EP1676582A1 Anti-coronavirus agent |
| 07/05/2006 | EP1676581A2 Polymer compositions for use in therapy |
| 07/05/2006 | EP1676580A1 Glycyrrhizin high-concentration preparation |
| 07/05/2006 | EP1676563A1 O/W emulsion comprising ascorbic acid or a derivative thereof |
| 07/05/2006 | EP1676534A1 Systems and methods for occluding a blood vessel |
| 07/05/2006 | EP1675942A2 Immunogenic composition and method of developing a vaccine based on cyclophilin a binding site |
| 07/05/2006 | EP1675888A1 Cationic polymers having degradable crosslinks |
| 07/05/2006 | EP1675876A2 Cyclodextrin amphiphilic derivatives, method for preparing same and uses thereof |
| 07/05/2006 | EP1675869A2 Stabilised compositions |